Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogenerics Bill From Reps. Eshoo And Barton “Expects” Limits On Substitution

Executive Summary

Interchangeability standards that come close to those sought by the Bush administration are contained in follow-on biologics legislation that is expected to be introduced shortly by Rep. Anna Eshoo, D-Calif

You may also be interested in...

Romney Advisor Leavitt Champions Part D As Model For Medicare Reform

As the presumptive architect of Republican presidential candidate Mitt Romney’s transition plan, former HHS Secretary Mike Leavitt would be a strong proponent for modeling future Medicare Parts A and B reforms on the Part D program.

Biosimilar Competition Debate: Must Products Be Interchangable To Generate Savings?

FTC hears arguments on whether the number of competitors, or their pharmacy-level substitutability, drives prices lower.

Follow-On Biologics Bill Could Be Shaped By Waxman/Dingell Fight For House Commerce Cmte.

Chairmanship would give Waxman more leverage to place regulatory flexibility into the biosimilars approval pathway.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts